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Lipopolysaccharide responsive beige-like anchor protein (LRBA) deficiency is a primary
immunodeficiency disorder (PID) that can cause a common variable immunodeficiency
(CVID)-like disease. The typical features of the disease are autoimmunity, chronic
diarrhea, and hypogammaglobulinemia. Neurological complications are also reported
in patients affected by LRBA deficiency. We describe a 7-year old female with an
acute cervical longitudinally extensive transverse myelitis (LETM) as a feature of LRBA
deficiency. This is the first case of LETM associated with LRBA deficiency described
in literature.
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INTRODUCTION
Lipopolysaccharide responsive beige-like anchor protein (LRBA) deficiency is a primary
immunodeficiency disorder (PID) described as a cause of common variable immunodeficiency
(CVID)-like disease (1). Several genes responsible of different subgroups of CVID have been
identified (2), but the majority of patients with CVID have an unknown genetic etiology. CVID
is a diagnosis of exclusion and so it is not surprising that CVID has heterogeneous clinical and
laboratory presentations (3). This disease can be caused by LRBA gene defects (1). LRBA is a
member of BEACH-WD40 protein family and it is expressed in several tissues (1, 4). The LRBA
gene is located on 4q31.3, contains 57 exons and encodes a protein containing 2851 amino acid
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residues (5). The LRBA protein is widely expressed in several
cell types including hematopoietic, neural, gastrointestinal,
and endocrine cells1 with an high expression especially in
lymphocytes (1, 6). This intracellular protein regulates the
lysosomal degradation of cytotoxic T lymphocytes antigen-4
(CTLA-4), an inhibitory checkpoint receptor on T cells (6). For
this reason patients with LRBA deficiency present an increase
in CTLA4 degradation with clinical signs similar to CTLA4
haploinsufficient individuals (7, 8). An increase expression
of LRBA is also described in many cancers, suggesting that
the protein promotes cell survival by inhibiting apoptosis (9).
The clinical features in patients affected by LRBA deficiency
are heterogeneous with age of presentation ranging from
2 months to 12 years. There is not a genotype-phenotype
correlation (10). LRBA deficiency can present with a wide
spectrum of clinical manifestations such as inflammatory bowel
disease (IBD)-like enteropathy, splenomegaly, pneumonia,
autoimmune disease (AID) like immune thrombocytopenia
purpura (ITP) and autoimmune hemolytic anemia (AIHA),
hypogammaglobulinemia, B-cell deficiency, reduction in
numbers of CD4+ T cells and regulatory T cells and autophagy
(1, 6, 10–13). LRBA deficiency is suspected on the basis of
heterogeneous clinical manifestations and immunological
dysregulation that can be found through blood tests. The
diagnosis currently relies on gene sequencing approaches or
on the detection of LRBA protein by flow cytometry (14). The
conventional treatment options for this disease have included
various immunosuppressive agents such as corticosteroids,
sirolimus, abatacept (soluble CTLA4- immunoglobulin fusion
protein) (6, 13, 15) or Hematopoietic Stem Cell Transplantation
(HSCT) (16). Neurological complications in patient affected by
LRBA deficiency are described (6, 10, 17) even if they are not one
of the typical features of the disease. We describe a 7-year old
female with an acute cervical longitudinally extensive transverse
myelitis (LETM) as a feature of LRBA deficiency. This is the
first case of LETM associated with LRBA deficiency described
in literature.
CASE REPORT
A 7-year-old female affected by LRBA deficiency was referred
to our hospital for fever, stiff neck, and right cervical
lymphadenopathy, that were unresponsive to anti-inflammatory
drugs and oral antibiotic therapy.
The patient was born to unrelated parents after a full-
term gestation. The birth weight was 2,420 g. The girl had
normal psychomotor development. From 6 months of age she
began to present recurrent severe infections during neutropenia
associated with diffuse lymphadenomegaly (inguinal, abscellar,
laterocervical, and mesenteric) and a diagnosis of autoimmune
neutropenia was made. At 18 months she was hospitalized
for cholelithiasis and hepatomegaly with autoimmune hepatitis
and initial signs of cirrhosis. At 2 years she developed
chronic diarrhea, hypertriglyceridemia, diffuse lipodystrophy,
and splenomegaly. Double negative T cells resulted high
1GeneCards. http://www.genecards.org/cgi-bin/carddisp.pl?gene=LRBA
(2.6% of total lymphocytes, normal value NV < 1.7%)
and FAS-mediated apoptosis was abnormal. Genetic tests
for autoimmune lymphoproliferative syndrome (ALPS) were
negative (FAS, FAS ligand and caspase 10). In the suspicion of
(ALPS)-like phenotype disease a therapy with mycophenolate
mofetil was started. After one year, for the worsening of
the lipodystrophy, anakinra, and then canakinumab were
administered with initial but temporary clinical improvement.
For persistent hypogammaglobulinemia the patient needed
monthly administrations of immunoglobulins. At 4.5 years
she underwent splenectomy for splenic abscess and started
prophylaxis with amoxicillin/clavulanate and antiplatelet therapy
with aspirin. At 5 years a mutation of Insulin Receptor
Substrate 1 (IRS-1) which could lead to insulin resistance,
leptin deficiency, and steatohepatitis, was detected. Therefore,
leptin was administered with reduction of liver dimension,
improvement of triglycerides level and no longer needing
of insulin. The patient started empirical immunosuppressive
therapy with prednisone (max 1mg/kg/day) and sirolimus due to
poor response to previous therapy. After few months the LRBA
deficiency was identified by next generation sequencing (NGS)
demonstrating double heterozygosity for two LRBA mutations;
one inherited from the father (non sense c.7681 C>T: p.Q2561X)
and one from the mother (splice disruption, c.1359 + 1G>A).
Only sirolimus therapy was ongoing at the time of admission to
our department.
On admission, she was conscious alert and oriented. Her
heart rate, respiratory rate, blood pressure and body temperature
were within normal range. She presented severe cervical
pain associated with left deviation of the neck. The low-
grade fever (37.6–37.8◦C) and the stiff neck appeared 10
days earlier, but the pain was initially moderate and the
patient was treated with anti-inflammatory drugs and oral
antibiotic therapy. She received the last administrations of
immunoglobulins 2 days before hospitalization. On examination,
a right laterocervical lymphadenomegaly was observed. After
few hours she developed right upper limb hyposthenia and
fecal incontinence. Blood exams showed an increase of white
blood cells (WBC) with low inflammatory markers (Table 1).
Microbiological analysis were negative (blood cultures, urine
culture, stool culture; Cytomegalovirus (CMV), Epstein Barr
Virus (EBV), Adenovirus and Toxoplasma gondii serology;
antistreptolysin antibodies, EBV, and CMV DNA copy number
quantification by real-time polymerase chain reaction). Magnetic
Resonance Imaging (MRI) was performed and showed extensive
spinal cord T2- hyperintense lesion extending from the
medulla oblongata to D3 level, with significant spinal cord
TABLE 1 | Blood exams.
Value Normal value
White blood cells (WBC) 20.840/mm3 4,500–13,500
Neutrophils 13.970/mm3 600–6,400
C-reactive protein (CRP) 6 mg/L <5
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FIGURE 1 | Cervical Magnetic Resonance Imaging (MRI) at clinical onset demonstrating a longitudinally extensive signal abnormality involving the cervical spinal cord,
extending from the obex to D3. The cord appears markedly swollen, both gray and white matter are involved, and post-contrast sequences demonstrate marked cord
enhancement between C3 and C5 (red arrows). Findings are compatible with acute longitudinally extensive transverse myelitis (LETM).
TABLE 2 | Cerebrospinal fluid (CSF) analysis.
Value Normal value
Cellularity 70 cells/uL (100% lymphocytes) <8
Glucose level 50 mg/dL 50–81
Protein content 1.35 g/L 0.15–0.45
IgG levels 82 mg/L <34 mg/L
Albumin 874 mg/L <320 mg/L
CSF/serum albumin quotient 23.75 <7
IgG-index 0.46 <0.70
swelling and marked contrast enhancement at C3–C5 level
which was compatible with acute Longitudinally Extensive
Transverse Myelitis (LETM) (Figure 1). Cerebrospinal fluid
(CSF) analysis revealed an increase of white blood cells
(100% lymphocytes), proteins and IgG levels with high
CSF/serum albumin quotient and normal IgG-index (Table 2).
CSF analysis for bacterial and viral infections yielded negative
results (Escherichia coli, Haemophilus influenzae, Listeria
monocytogenes, Neisseria meningitidis, Streptococcus agalatiae,
Streptococcus pneumoniae, EBV, CMV, Herpes simplex
Virus 1 (HSV1), Herpes simplex Virus 2 (HSV2), Human
parechovirus, Varicella zoster virus (VZV), Enterovirus and
Cryptococcus neoformans). Serum antibodies to myelin
oligodendrocyte glycoprotein (MOG live cell-based assay)
and aquaporin-4 (AQP4 fixed cell-based assay, Euroimmune
commercial kit-4) were negative. Isoelectrofocusing revealed
the presence of oligoclonal bands in both serum and CSF type
4 “mirror” pattern. An extensive autoimmune screening was
negative [antinuclear antibodies (ANA), anti-double stranded
DNA antibodies (anti-ds-DNA), anti-neutrophil cytoplasmic
antibodies (ANCA, p-ANCA, c-ANCA, a-ANCA, anti PR3,
anti myeloperoxidase antibodies MPO), anti-saccharomyces
cerevisiae antibodies (ASCA), anti-smooth muscle antibody
(ASMA), anti-liver-kidney microsome antibodies (LKM), anti-
insulin antibody, TSH receptor antibodies (TRAb)]. The patient
received intravenous dexamethasone at the dosage of 0.15 mg/kg
for 27 days followed by a 9-week tapering dose of oral steroids
which resulted in a rapid clinical improvement. Follow-up
MRIs, performed after 20 and 55 days, respectively, (Figure 2),
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FIGURE 2 | Follow-up MRI scans at 20 (A) and 55 (B) days, showing progressive reduction of the spinal cord swelling and contrast enhancement. In (B), contrast
enhancement has completely regressed, due to blood-brain barrier restoration, and the spinal cord shows a near-normal appearance with no residual disease. No
spinal cord atrophy is noted.
showed progressive improvement of spinal cord oedema and
enhancement in parallel with a complete clinical recovery. The
patient was then transferred to another institution for stem cell
transplantation and the last follow-up MRI before transplant she
was referred completely negative (image not available).
DISCUSSION
Patients with LRBA deficiency typically present
immunodeficiency, inflammatory bowel disease (IBD)-like
enteropathy, and autoimmune disease (AID) (1, 11–13). Some
studies report an imbalance in Th subsets, in particular in
Th1-like Th17 and Treg cells and their corresponding cytokines
in LRBA deficiency. This condition might be important in
the immunopathogenesis of autoimmunity and enteropathy
(18). According to some publications a defect of LRBA
can be associated with an IPEX-like (19) or ALPS-like (20)
clinical presentation thus similar to our patient’s phenotype.
Neurological complications of the disease have been described
(6, 10, 17). Alkhairy et al. (10) reported that neurological features
occur in 23% of patients. The authors, with the exception of
myasthenia gravis which has an autoimmune etiology, describe
patients with cerebral lesions and nervous tissue atrophy.
They report two patients with cerebral granulomas, one with
granuloma-like lesion with demyelination resulting in unilateral
optic nerve atrophy, one with unilateral optic nerve atrophy,
one with cerebral and cerebellar atrophy and another with
parietal lobe lesion complicated by seizures (10). Tesi et al.
described a patient with LRBA deficiency complicated with an
acute disseminated encephalomyelitis (ADEM) who underwent
hematopoietic stem cell transplant (17). ADEM has also been
described in one CTLA-4 haploinsufficient patient (7) and in
patient with CVID (21). To the best of our knowledge this is
the first ever reported patient with LETM associated with LRBA
deficiency. We believe that the high value of white blood count is
a consequence of inflammation. The exclusion of infectious and
neoplastic nature of the lesion, together with the good response
to steroid treatment, allow us to consider it an inflammatory
seronegative LETM. This condition is observed in a group of
inflammatory autoimmune disorders, often in the context of
neuromyelitis optica spectrum disorders (NMOSD) (22–25).
These disorders are mostly related to the presence of antibodies
against aquaporin (AQP4) or against myelin oligodendrocyte
glycoprotein (MOG) (24–26). However, in some patients AQP4-
Antibodies and MOG-Antibodies are lacking, thus these patients
are usually labeled “double seronegative LETM” or “seronegative
LETM” (26, 27). We consider LETM as one of the possible
immune-mediated manifestations that compose the clinical
spectrum of LRBA deficiency.
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